In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains

Klein, Niklas and Jantsch, Jonathan and Simon, Michaela and Roedel, Juergen and Becker, Soeren L. and Serr, Annerose and Steinmann, Joerg and Ehrentraut, Stefan F. and Mollitor, Ernst and Hischebeth, Gunnar T. R. (2025) In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains. INFECTION, 53 (3). pp. 1061-1068. ISSN 0300-8126, 1439-0973

Full text not available from this repository. (Request a copy)

Abstract

PurposeThe emergence of multidrug-resistant P. aeruginosa isolates poses a challenge to healthcare systems worldwide. Rising numbers in deaths, duration of hospitalization as well as failing treatments prove the hazards posed by these pathogens. This and the lack of promising therapeutic options highlight the urgency of antibiotic drug development. As interim solution or alternative to the development of new antibiotic drugs, investigation of novel combinations of existing antibiotic drugs can be an economic and swift approach. Therefore, this study addresses the evaluation of in vitro activity of the antibiotic combination of ceftazidime-avibactam/aztreonam against MBL-producing P. aeruginosa strains.MethodsWe tested 153 isolates from six university hospitals via microdilution against their susceptibility to meropenem, aztreonam, ceftazime-avibactam and the minimal inhibitory concentration of the combination of ceftazidime-avibactam/aztreonam. 64 isolates produced carbapenemases of which 61 were VIM-, 2 NDM- and 1 OXA-producer.ResultsWe were able to show that the synergetic effects of this regimen with an avibactam concentration of 4 mg/l and an aztreonam concentration of 16 mg/l could successfully lower the number of MBL-producing isolates that showed a high minimal inhibitory concentration compared to a carbapenemase-negative control group in vitro.ConclusionThe antibiotic combination consisting of ceftazidime-avibactam/aztreonam represents a possible approach to the treatment of patients infected with multidrug-resistant P. aeruginosa isolates.

Item Type: Article
Uncontrolled Keywords: LACTAMASE; AVIBACTAM; ENTEROBACTERIACEAE; SUSCEPTIBILITY; RESISTANCE; BACTERIA; Pseudomonas aeruginosa; MBL; Ceftazidime; Avibactam; Aztreonam; Multi drug resistance
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene
Depositing User: Dr. Gernot Deinzer
Date Deposited: 31 Mar 2026 08:40
Last Modified: 31 Mar 2026 08:40
URI: https://pred.uni-regensburg.de/id/eprint/65336

Actions (login required)

View Item View Item